MARKET

TGTX

TGTX

TG Therapeutics
NASDAQ

Real-time Quotes | Nasdaq Last Sale

41.71
-1.57
-3.63%
After Hours: 41.71 0 0.00% 17:22 03/08 EST
OPEN
43.42
PREV CLOSE
43.28
HIGH
44.61
LOW
41.47
VOLUME
1.33M
TURNOVER
--
52 WEEK HIGH
56.74
52 WEEK LOW
6.34
MARKET CAP
5.86B
P/E (TTM)
-17.4002
1D
5D
1M
3M
1Y
5Y
TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting
NEW YORK, March 04, Mar 04, 2021 (GLOBE NEWSWIRE via COMTEX) -- NEW YORK, March 04, 2021 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today...
GlobeNewswire · 4d ago
TG Therapeutics Says To Presents Results From ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab In Multiple Sclerosis At Upcoming American Academy Of Neurology Annual Meeting
TG Therapeutics to Present Results from the ULTIMATE I & II Phase 3 Trials Evaluating Ublituximab in Multiple Sclerosis at the Upcoming American Academy of Neurology 73rd Annual Meeting NEW YORK, March 04, 2021
Benzinga · 4d ago
TG Therapeutics to Present at the H.C. Wainwright Global Life Sciences Conference
TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company's Executive Chairman and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference, being held virtually March 9 - 10, 2021. The pres...
GlobeNewswire · 4d ago
Analyst Actions: B. Riley Lowers TG Therapeutics' Price Target to $91 from $95, Keeps Buy Rating
MT Newswires · 4d ago
Company News for Mar 3, 2021
Zacks.com · 5d ago
Company News for Mar 3, 2021
Companies in The News Are: KSS,AZO,TGTX,KTB
Zacks · 5d ago
Is TG Therapeutics, Inc. (NASDAQ:TGTX) Popular Amongst Insiders?
The big shareholder groups in TG Therapeutics, Inc. ( NASDAQ:TGTX ) have power over the company. Institutions often own...
Simply Wall St. · 5d ago
TG Therapeutics (TGTX) Reports Q4 Loss, Lags Revenue Estimates
Zacks.com · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of TGTX. Analyze the recent business situations of TG Therapeutics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 7 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average TGTX stock price target is 75.33 with a high estimate of 91.00 and a low estimate of 65.00.
EPS
Institutional Holdings
Institutions: 333
Institutional Holdings: 115.63M
% Owned: 82.25%
Shares Outstanding: 140.59M
TypeInstitutionsShares
Increased
78
16.84M
New
99
3.09M
Decreased
57
6.32M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-2.04%
Pharmaceuticals & Medical Research
-0.50%
Key Executives
Chairman/President/Chief Executive Officer/Director
Michael Weiss
Chief Financial Officer/Treasurer/Secretary
Sean Power
Chief Technology Officer
Kelly Ross
Independent Director
Laurence Charney
Independent Director
Yann Echelard
Independent Director
Kenneth Hoberman
Independent Director
Daniel Hume
Independent Director
William Kennedy
Independent Director
Sagar Lonial
No Data
About TGTX
TG Therapeutics, Inc. (TG) is a biopharmaceutical company focused on the acquisition, development and commercialization of treatments for B-cell malignancies and autoimmune diseases. As of December 31, 2016, the Company was developing two therapies targeting hematological malignancies. TG-1101 (ublituximab) is a glycoengineered monoclonal antibody that targets a specific epitope on the cluster of differentiation (CD20) antigen found on mature B-lymphocytes. The Company is also developing TGR-1202, an orally available Phosphoinositide 3-kinase (PI3K) delta inhibitor. Both TG-1101 and TGR-1202 are in clinical development for patients with hematologic malignancies. The Company also has pre-clinical programs focusing on developing interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and anti- programmed cell death ligand 1 (PD-L1) and anti- glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies.

Webull offers kinds of TG Therapeutics Inc stock information, including NASDAQ:TGTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, TGTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading TGTX stock methods without spending real money on the virtual paper trading platform.